{"entity":{"id":"nct05479994","kind":"trial","name":"Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","aka":[],"tldr":"A phase 2 trial of Sonrotoclax in non-Hodgkin lymphoma and chronic lymphocytic leukaemia, run by BeiGene, active and no longer recruiting.","summary":"Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma is a phase 2 interventional study registered as NCT05479994 by BeiGene, with 100 participants enrolled, started 2022-10-25 and due to reach its primary completion in 2025-01-24. Interventions recorded: BGB-11417.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05479994","url":"https://clinicaltrials.gov/study/NCT05479994"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","cll"],"sections":[],"technologies":[],"targets":[],"drugs":["sonrotoclax"],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05479994","phase":"2","setting":"A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","sponsor":"BeiGene","enrolled":100,"outcomes":[]},"route":"/trials/nct05479994/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}]}}